Results 11 to 20 of about 556,267 (253)

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma

EBioMedicine, 2020
Background: Vorolanib (X-82, CM082) is a multi-target tyrosine kinase inhibitor. This study aimed to evaluate the tolerability, safety, pharmacokinetics and antitumor activities of vorolanib plus everolimus (an inhibitor of mammalian target of rapamycin).
Xinan Sheng, Xieqiao Yan, Zhihong Chi, Chuanliang Cui, Lu Si, Bixia Tang, Siming Li, Lili Mao, Bin Lian, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Lieming Ding, Li Mao, Jun Guo   +16 more
doaj   +1 more source

Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort

Journal for ImmunoTherapy of Cancer, 2021
Background Although the Society for Immunotherapy of Cancer (SITC) Immunotherapy Resistance Taskforce recently defined primary and secondary resistance to anti-programmed cell death protein 1 (anti-PD-1) therapy, there is lack of real-world data ...
Xiaoling Yang, Keith Flaherty, Jun Guo, Xue Bai, Michelle Kim, Gyulnara Kasumova, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoting Wei, Donald Lawrence, Christine Freedman, Riley Fadden, Krista Rubin, Tatyana Sharova, Dennie Frederick, Genevieve Boland   +16 more
doaj   +1 more source

Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy

Journal of Translational Medicine, 2019
Background Melanoma is one of the most aggressive cancers with extremely poor prognosis, and the median survival time for stage IV patients is approximately 6 to 8 months.
Longwen Xu, Zhiyuan Cheng, Chuanliang Cui, Xiaowen Wu, Huan Yu, Jun Guo, Yan Kong   +6 more
doaj   +1 more source

Efficacy and Safety of Vemurafenib in Acral and Mucosal Melanoma Patients with BRAF Gene Mutation

Zhongliu Fangzhi Yanjiu, 2018
Objective To explore the efficacy and safety of Vemurafenib in acral and mucosal melanoma patients with BRAF gene mutation. Methods We retrospectively analyzed the clinical data of 24 patients diagnosed as BRAF gene-mutant acral melanoma (AM) or mucosal ...
WEI Xiaoting, BAI Xue, MAO Lili, CHI Zhihong, SHENG Xi'nan, CUI Chuanliang, WANG Xuan, LIAN Bin, TANG Bixia, YAN Xieqiao, LI Siming, ZHOU Li, GUO Jun, SI Lu   +13 more
doaj   +1 more source

Current strategies to diagnose and manage positive surgical margins and local recurrence after partial nephrectomy

Asian Journal of Urology, 2022
Objective: No standard strategy for diagnosis and management of positive surgical margin (PSM) and local recurrence after partial nephrectomy (PN) are reported in literature.
Umberto Carbonara, Daniele Amparore, Cosimo Gentile, Riccardo Bertolo, Selcuk Erdem, Alexandre Ingels, Michele Marchioni, Constantijn H.J. Muselaers, Onder Kara, Laura Marandino, Nicola Pavan, Eduard Roussel, Angela Pecoraro, Fabio Crocerossa, Giuseppe Torre, Riccardo Campi, Pasquale Ditonno   +16 more
doaj   +1 more source

Correction to: Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy

Journal of Translational Medicine, 2019
Following publication of the original article [1], the authors reported errors in Figures 2, 3 and Figure 3 ‘continued’
Longwen Xu, Zhiyuan Cheng, Chuanliang Cui, Xiaowen Wu, Huan Yu, Jun Guo, Yan Kong   +6 more
doaj   +1 more source

Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse

Scientific Reports, 2021
Calcineurin inhibitors, such as Cyclosporin (CsA), are the mainstay of anti-rejection therapy in solid organ transplants but can paradoxically induce progressive nephropathy characterised by renal dysfunction and interstitial fibrosis.
Long T. Nguyen, Sonia Saad, Ying Shi, Rosy Wang, Angela S. Y. Chou, Anthony Gill, Yimin Yao, Wolfgang Jarolimek, Carol A. Pollock   +8 more
doaj   +1 more source

Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure

Translational Oncology, 2018
OBJECTIVE: Asian melanoma patients, predominantly comprised of acral and mucosal subtypes, might not benefit from immunotherapy and targeted therapy as much as Caucasian patients.
ChuanLiang Cui, Li Zhou, Bin Lian, Lu Si, XiNan Sheng, ZhiHong Chi, Yan Kong, Xuan Wang, BiXia Tang, LiLi Mao, SiMing Li, Jie Dai, XieQiao Yan, Xue Bai, Jun Guo   +14 more
doaj   +1 more source

Efficacy and Safety of Paclitaxel, Ifosfamide and Cisplatin as First-line Treatment on Patients with Intermediate- or Poor-risk Advanced Testicular Cancer

Zhongliu Fangzhi Yanjiu, 2018
Objective To assess the efficacy and safety of paclitaxel, ifosfamide and cisplatin (TIP) as the first-line treatment for the patients with intermediate- or poor-risk testicular cancer retrospectively.
ZHOU Li, CHI Zhihong, CUI Chuanliang, SHENG Xi'nan, SI Lu, TANG Bixia, MAO Lili, WANG Xuan, YAN Xieqiao, LIAN Bin, LI Siming, BAI Xue, GUO Jun   +12 more
doaj   +1 more source

Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study

BMC Cancer, 2023
Background Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block the binding of PD-1 with its ligands PD-L1 and PD-L2.
Chuanliang Cui, Yu Chen, Zhiguo Luo, Zhengyun Zou, Yu Jiang, Hongming Pan, Qingxia Fan, Jianfu Zhao, Qing Xu, Renbing Jiang, Xuan Wang, Taiyang Ma, Zhen Guo, Lu Si, Zhihong Chi, Xinan Sheng, Yiwei Dou, Qian Tan, Di Wu, Jun Guo   +19 more
doaj   +1 more source